Cymabay Therapeutics
CBAY
CBAY was delisted on the 21st of March, 2024.
113 hedge funds and large institutions have $216M invested in Cymabay Therapeutics in 2021 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 38 increasing their positions, 26 reducing their positions, and 24 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
46% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 26
27% more capital invested
Capital invested by funds: $169M → $216M (+$46.5M)
0% more funds holding
Funds holding: 113 → 113 (0)
0% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 24
31% less call options, than puts
Call options by funds: $1.38M | Put options by funds: $1.99M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$7.59M |
| 2 |
ACM
Altium Capital Management
New York
|
+$6.64M |
| 3 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$4.8M |
| 4 |
CC
Commodore Capital
New York
|
+$4.75M |
| 5 |
AAA
Affinity Asset Advisors
New York
|
+$4.26M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KPWS
Kestra Private Wealth Services
Austin,
Texas
|
-$1.83M |
| 2 |
Renaissance Technologies
New York
|
-$1.13M |
| 3 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$1.1M |
| 4 |
Two Sigma Advisers
New York
|
-$746K |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$420K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
126
Principal Financial Group
Des Moines,
Iowa
| – | -$50K | -13,684 | Closed |
|
127
Simplex Trading
Chicago,
Illinois
| – | -$42.5K | -11,198 | Closed |
|
|
RJFSA
128
Raymond James Financial Services Advisors
St. Petersburg,
Florida
| – | -$40K | -11,091 | Closed |
|
129
AQR Capital Management
Greenwich,
Connecticut
| – | -$39K | -10,578 | Closed |
|
|
LCM
130
LCM Capital Management
Chicago,
Illinois
| – | -$37K | -10,000 | Closed |
|
|
S
131
SignatureFD
Atlanta,
Georgia
| – | -$28K | -7,700 | Closed |
|
|
PCM
132
Penserra Capital Management
Orinda,
California
| – | -$5K | -1,580 | Closed |
|
|
PHK
133
Point72 Hong Kong
Hong Kong
| – | -$2K | -610 | Closed |
|
134
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
| – | +$30 | +8 | New |
|
CBAY Hedge Fund Activity: Q4 2021 in Review
113 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q4 2021, worth a combined $216M — up 27% from $169M a quarter earlier.
Fund positioning in CBAY was balanced in Q4 2021: 24 funds opened new positions, 24 closed out, 38 added to existing stakes and 26 trimmed.
The largest buyer was Nantahala Capital Management, opening a new position worth an estimated $7.59M. The largest seller was Kestra Private Wealth Services, exiting entirely with an estimated $1.83M sold.
- 113 institutional investors held Cymabay Therapeutics (CBAY) as of Q4 2021, unchanged from Q3 2021.
- Funds reported $216M of Cymabay Therapeutics stock for Q4 2021, up 27% quarter-over-quarter.
- 24 funds opened new Cymabay Therapeutics positions in Q4 2021 and 24 closed out, a net change of 0 holders.
- The largest Cymabay Therapeutics buyer in Q4 2021 was Nantahala Capital Management, an estimated $7.59M added.
- The largest Cymabay Therapeutics seller in Q4 2021 was Kestra Private Wealth Services, an estimated $1.83M sold.
Based on aggregated 13F filings for Q4 2021.